ClinicalTrials.gg
CompletedNCT00339183Updated Sep 23, 2022Results posted

Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone

A Phase 3 interventional study of Panitumumab and FOLFIRI in Metastatic Colorectal Cancer, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-23.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,186
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.

Enrollment
2nd of 88
1,186 · median 70
Started
2006
with 5 others
Phase 3
14 of 90
2 open now
Registered
11th of 90
by date
Lead sponsor
20 of 90
Amgen

Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 2nd largest by enrollment of the 88 interventional ones that give a count, is one of 6 that started in 2006, is one of 14 in phase 3, and was the 11th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing panitumumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the treatment effect of panitumumab plus FOLFIRI compared to FOLFIRI alone as second line therapy for metastatic colorectal cancer.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • Oncology
  • Cancer
  • Metastatic Colorectal Cancer
  • EGFr
  • Panitumumab
  • Clinical Trial
  • Amgen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Man or woman at least 18 years old
  • Diagnosis of colorectal cancer (mCRC)
  • One and only one chemotherapy regimen for mCRC consisting of 5-FU -based chemotherapy
  • Radiologically documented disease progression per modified (RECIST) criteria during treatment or within 6 months of last dose of first-line chemotherapy
  • At least 1 uni-dimensionally of at least 20 mm per modified RECIST
  • (ECOG) status of 0, 1, or 2
  • Paraffin-embedded tumor tissue from the primary tumor or metastasis available for central analyses
  • Adequate hematologic, renal, and hepatic functions
  • Negative pregnancy test within 72 hours of enrollment
  • Other protocol-specified criteria may apply

Exclusion criteria

Exclusion Criteria:

  • History of or known presence of central nervous system (CNS)
  • History of another primary cancer within 5 years of randomization
  • Prior irinotecan therapy
  • Prior anti-epidermal growth factor receptor (EGFr) antibody therapy or treatment with small molecule EGFr inhibitors
  • Any agent or therapy within 30 days before randomization
  • Known allergy or to irinotecan, 5-FU or leucovorin
  • History of interstitial lung disease or evidence of interstitial lung disease on baseline chest computed tomography (CT) scan
  • Active inflammatory bowel disease or other bowel disease causing chronic diarrhea
  • Known positive tests for human immunodefiency virus (), viris (HCV), acute or chronic active virus (HBV)
  • Major surgery within 28 days of randomization or minor surgical procedure within 14 days of randomization
  • Pregnant or breast-feeding
  • Man or woman of not consenting to use adequate methods or abstinence during the course of the study and for 6 months after last study drug administration (women) or 1 month after last study drug administration (men)
  • Other protocol-specified criteria may apply
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,186 participants (actual)

Study arms

  • Experimental
    Panitumumab Plus FOLFIRI

    Participants received panitumumab as an intravenous (IV) infusion at a dose of 6 mg/kg plus a standard chemotherapy regimen (FOLFIRI) consisting of 5-fluorouracil (5-FU), leucovorin and irinotecan. Treatment was administered in cycles every two weeks.

    Drug: Panitumumab · Drug: FOLFIRI

  • Active comparator
    FOLFIRI Alone

    Participants received standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment is administered in cycles every two weeks.

    Drug: FOLFIRI

Interventions

  • Panitumumab was administered by IV infusion on Day 1 of each 14-day cycle, just before administration of FOLFIRI chemotherapy.

    Also known as: Vectibix®

  • DrugFOLFIRI

    FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 racemate (or 200 mg/m\^2 I-leucovorin), 5-FU bolus 400 mg/m\^2, 5-FU infusion 2400 mg/m\^2.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    Progression-free survival was defined as the time from randomization to first disease progression per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria or death, based on independent central radiological assessment. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.

    Time frame: From randomization until the data cut-off date of 8 April 2008. Maximum follow-up time was 17 months.

  2. Overall Survival

    Overall survival was defined as the time from randomization to the date of death. Participants who had not died by the analysis data cutoff date had their time of death censored at their last contact date.

    Time frame: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months

Secondary outcomes

  1. Percentage of Participants With an Objective Response

    Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on study, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders.

    Time frame: Every 8 weeks until disease progression up to the data cut-off date of 30 April 2009. Maximum time on follow-up was 33 months.

  2. Time to Disease Progression

    Time to progression was defined as the time from the randomization date to the date of first observed disease progression per the modified RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.

    Time frame: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months

  3. Duration of Response

    Calculated only for those participants with an objective response as the time from the first objective response (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified-RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.

    Time frame: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months

  4. Number of Participants With Adverse Events (AEs)

    A serious adverse event (SAE) is defined by regulatory authorities as one that • is fatal • is life threatening (places the subject at immediate risk of death) • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: "Is there a reasonable possibility that the event may have been caused by the study treatment?"

    Time frame: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months.

07

Results

Posted May 6, 2014

Participant flow

First patient enrolled 30 June 2006; Last patient enrolled 13 March 2008.

Participant flow — Overall Study
MilestonePanitumumab Plus FOLFIRIFOLFIRI Alone
Started591595
Received study drug588593
Completed470490
Not completed121105
Withdrew: Adverse event53
Withdrew: Withdrawal by subject1619
Withdrew: Physician decision24
Withdrew: Lost to follow-up1717
Withdrew: Protocol-specified criteria128
Withdrew: Missing reason31
Withdrew: Other4640
Withdrew: Ongoing2013

Outcome measures

PrimaryProgression-free Survival (PFS)

Progression-free survival was defined as the time from randomization to first disease progression per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria or death, based on independent central radiological assessment. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.

Time frame:
From randomization until the data cut-off date of 8 April 2008. Maximum follow-up time was 17 months.
Reported as:
Median · months
Progression-free Survival (PFS)
monthsWild-type KRAS - Panitumumab Plus FOLFIRIWild-type KRAS - FOLFIRI AloneMutant KRAS - Panitumumab Plus FOLFIRIMutant KRAS - FOLFIRI Alone
Progression-free Survival (PFS)5.9 (5.5 to 6.7)3.9 (3.7 to 5.3)5.0 (3.8 to 5.6)4.9 (3.6 to 5.6)
Statistical analysis
  • Wild-type KRAS - Panitumumab Plus FOLFIRI vs Wild-type KRAS - FOLFIRI Alone · Stratified log-rank test · p = 0.0036 · Normal score: -2.91A normal score \<0 indicates fewer than expected events for the Panitumumab plus FOLFIRI arm and therefore a longer progression-free survival time.
  • Mutant KRAS - Panitumumab Plus FOLFIRI vs Mutant KRAS - FOLFIRI Alone · Stratified log-rank test · p = 0.1448 · Normal score: -1.46A normal score \<0 indicates fewer than expected events for the Panitumumab plus FOLFIRI arm and therefore a longer progression-free survival time.
PrimaryOverall Survival

Overall survival was defined as the time from randomization to the date of death. Participants who had not died by the analysis data cutoff date had their time of death censored at their last contact date.

Time frame:
From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months
Reported as:
Median · months
Overall Survival
monthsWild-type KRAS - Panitumumab Plus FOLFIRIWild-type KRAS - FOLFIRI AloneMutant KRAS - Panitumumab Plus FOLFIRIMutant KRAS - FOLFIRI Alone
Overall Survival14.5 (13.0 to 16.0)12.5 (11.2 to 14.2)11.8 (10.4 to 13.3)11.1 (10.3 to 12.4)
Statistical analysis
  • Wild-type KRAS - Panitumumab Plus FOLFIRI vs Wild-type KRAS - FOLFIRI Alone · Stratified log-rank test · p = 0.1154 · Normal score: -1.57A normal score \<0 indicates fewer than expected events for the Panitumumab plus FOLFIRI arm and therefore a longer overall survival time.
  • Mutant KRAS - Panitumumab Plus FOLFIRI vs Mutant KRAS - FOLFIRI Alone · Stratified log-rank test · p = 0.5503 · Normal score: -0.60A normal score \<0 indicates fewer than expected events for the Panitumumab plus FOLFIRI arm and therefore a longer overall survival time.
SecondaryPercentage of Participants With an Objective Response

Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on study, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders.

Time frame:
Every 8 weeks until disease progression up to the data cut-off date of 30 April 2009. Maximum time on follow-up was 33 months.
Reported as:
Number · percentage of participants
Percentage of Participants With an Objective Response
percentage of participantsWild-type KRAS - Panitumumab Plus FOLFIRIWild-type KRAS - FOLFIRI AloneMutant KRAS - Panitumumab Plus FOLFIRIMutant KRAS - FOLFIRI Alone
Percentage of Participants With an Objective Response35.35 (29.92 to 41.08)9.82 (6.63 to 13.89)13.36 (9.26 to 18.43)13.92 (9.78 to 19.00)
Statistical analysis
  • Wild-type KRAS - Panitumumab Plus FOLFIRI vs Wild-type KRAS - FOLFIRI Alone · Stratified exact test · p = <0.0001 · Odds ratio (or): 5.33 · 95% CI 3.21 to 8.60The odds ratio is defined as the odds of having an objective response in the panitumumab plus arm relative to the odds on the FOLFIRI alone arm.
  • Mutant KRAS - Panitumumab Plus FOLFIRI vs Mutant KRAS - FOLFIRI Alone · Stratified exact test · p = 1.0000 · Odds ratio (or): 1.00 · 95% CI 0.56 to 1.76The odds ratio is defined as the odds of having an objective response in the panitumumab plus arm relative to the odds on the FOLFIRI alone arm.
SecondaryTime to Disease Progression

Time to progression was defined as the time from the randomization date to the date of first observed disease progression per the modified RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.

Time frame:
From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months
Reported as:
Median · months
Time to Disease Progression
monthsWild-type KRAS - Panitumumab Plus FOLFIRIWild-type KRAS - FOLFIRI AloneMutant KRAS - Panitumumab Plus FOLFIRIMutant KRAS - FOLFIRI Alone
Time to Disease Progression7.3 (5.9 to 7.5)5.3 (3.9 to 5.7)5.5 (4.5 to 5.7)5.5 (4.2 to 5.7)
SecondaryDuration of Response

Calculated only for those participants with an objective response as the time from the first objective response (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified-RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.

Time frame:
From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months
Reported as:
Median · months
Duration of Response
monthsWild-type KRAS - Panitumumab Plus FOLFIRIWild-type KRAS - FOLFIRI AloneMutant KRAS - Panitumumab Plus FOLFIRIMutant KRAS - FOLFIRI Alone
Duration of Response7.6 (6.7 to 9.4)6.6 (5.7 to 10.4)6.0 (5.4 to 7.4)7.4 (4.0 to 8.1)
SecondaryNumber of Participants With Adverse Events (AEs)

A serious adverse event (SAE) is defined by regulatory authorities as one that • is fatal • is life threatening (places the subject at immediate risk of death) • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: "Is there a reasonable possibility that the event may have been caused by the study treatment?"

Time frame:
From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months.
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsPanitumumab Plus FOLFIRIFOLFIRI Alone
Any adverse event584573
Serious adverse event232175
Leading to discontinuation of any study drug12364
Treatment-related adverse event (TRAE)577542
Serious treatment-related adverse event12490
TRAE leading to discontinuation of any study drug9734

Adverse events

Collected over The median treatment period was approximately 6.2 months in the Panitumumab plus FOLFIRI arm, and 4.7 months in the FOLFIRI Alone arm.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panitumumab Plus FOLFIRI—232/587 (39.5%)575/587 (98%)
FOLFIRI Alone—175/594 (29.5%)546/594 (91.9%)
Most frequent serious events
Showing 10 of 287
Most frequent serious events
EventPanitumumab Plus FOLFIRIFOLFIRI Alone
DiarrhoeaGastrointestinal disorders33/58723/594
PyrexiaGeneral disorders24/58716/594
DehydrationMetabolism and nutrition disorders20/58711/594
VomitingGastrointestinal disorders17/58713/594
Pulmonary embolismRespiratory, thoracic and mediastinal disorders17/58710/594
Febrile neutropeniaBlood and lymphatic system disorders11/58716/594
Abdominal painGastrointestinal disorders12/58713/594
NauseaGastrointestinal disorders12/5875/594
NeutropeniaBlood and lymphatic system disorders6/58712/594
Colorectal cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)9/58710/594
Most frequent other events
Showing 10 of 43
Most frequent other events
EventPanitumumab Plus FOLFIRIFOLFIRI Alone
DiarrhoeaGastrointestinal disorders372/587321/594
RashSkin and subcutaneous tissue disorders330/58738/594
NauseaGastrointestinal disorders276/587269/594
NeutropeniaBlood and lymphatic system disorders207/587209/594
FatigueGeneral disorders203/587186/594
VomitingGastrointestinal disorders154/587162/594
AnorexiaMetabolism and nutrition disorders146/58793/594
Dermatitis acneiformSkin and subcutaneous tissue disorders141/5873/594
ConstipationGastrointestinal disorders139/587125/594
AlopeciaSkin and subcutaneous tissue disorders124/587136/594

Baseline characteristics

Age, Continuous
Age, Continuous(years)Panitumumab Plus FOLFIRIFOLFIRI AloneTotal
Mean60.2 ± 10.560.9 ± 10.660.6 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)Panitumumab Plus FOLFIRIFOLFIRI AloneTotal
Female245219464
Male346376722
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Panitumumab Plus FOLFIRIFOLFIRI AloneTotal
White or Caucasian5685691137
Black or African American459
Hispanic or Latino235
Asian235
Japanese91120
Native Hawaiian or Other Pacific Islander112
Aborigine213
Other325
KRAS Status
KRAS Status(participants)Panitumumab Plus FOLFIRIFOLFIRI AloneTotal
Wild-type KRAS303294597
Mutant KRAS238248486
Unevaluable KRAS5053103
Prior Oxaliplatin Exposure for mCRC
Prior Oxaliplatin Exposure for mCRC(participants)Panitumumab Plus FOLFIRIFOLFIRI AloneTotal
No179182361
Yes412413825
Prior Bevacizumab Exposure for mCRC
Prior Bevacizumab Exposure for mCRC(participants)Panitumumab Plus FOLFIRIFOLFIRI AloneTotal
No480483963
Yes111112223
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Panitumumab Plus FOLFIRIFOLFIRI AloneTotal
Grade 0 or 15645651129
Grade 2273057
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tian Y, Sidhu R. Final results from a randomized phase 3 study of FOLFIRI +/- panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol. 2014 Jan;25(1):107-16. doi: 10.1093/annonc/mdt523. Erratum In: Ann Oncol. 2014 Mar;25(3):757. Ann Oncol. 2014 Mar;25(3):757. doi: 10.1093/annonc/mdu002. PubMed 24356622 ↗
  • Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010 Nov 1;28(31):4706-13. doi: 10.1200/JCO.2009.27.6055. Epub 2010 Oct 4. PubMed 20921462 ↗
  • Author and team decided to wait for CALGB RAS data presented Sept 29 at ESMO.
  • Peeters M, Price T, Taieb J, Geissler M, Rivera F, Canon JL, Pentheroudakis G, Koukakis R, Burdon P, Siena S. Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. Br J Cancer. 2018 Aug;119(3):303-312. doi: 10.1038/s41416-018-0165-z. Epub 2018 Jul 17. PubMed 30013091 ↗
  • Shi Y, Wan X, Tan C, Li J, Peng L. Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer. Adv Ther. 2020 Feb;37(2):847-859. doi: 10.1007/s12325-019-01214-y. Epub 2020 Jan 4. PubMed 31902066 ↗
  • Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, Tabernero J, Douillard JY, Andre T, Peeters M. Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies. Clin Colorectal Cancer. 2018 Sep;17(3):170-178.e3. doi: 10.1016/j.clcc.2018.03.005. Epub 2018 Mar 8. PubMed 29627309 ↗
  • Peeters M, Oliner KS, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, He P, Yu H, Koukakis R, Terwey JH, Jung AS, Sidhu R, Patterson SD. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. Clin Cancer Res. 2015 Dec 15;21(24):5469-79. doi: 10.1158/1078-0432.CCR-15-0526. Epub 2015 Sep 4. PubMed 26341920 ↗
  • Peeters M, Kafatos G, Taylor A, Gastanaga VM, Oliner KS, Hechmati G, Terwey JH, van Krieken JH. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. Eur J Cancer. 2015 Sep;51(13):1704-13. doi: 10.1016/j.ejca.2015.05.017. Epub 2015 Jun 3. PubMed 26049686 ↗
  • Weeraratne D, Chen A, Pennucci JJ, Wu CY, Zhang K, Wright J, Perez-Ruixo JJ, Yang BB, Kaliyaperumal A, Gupta S, Swanson SJ, Chirmule N, Starcevic M. Immunogenicity of panitumumab in combination chemotherapy clinical trials. BMC Clin Pharmacol. 2011 Nov 9;11:17. doi: 10.1186/1472-6904-11-17. PubMed 22070868 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2006 to primary completion in Apr 2009, 33 months.

Results were first posted in May 2014, 5 years 1 month after primary completion. A results delay was requested in Jul 2010.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 33 months is below that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2006
First posted
Jun 20, 2006
StartActual
Jun 30, 2006
Primary completionActual
Apr 1, 2009
CompletionActual
Nov 1, 2010
Results delay requested
Jul 20, 2010
Results first posted
May 6, 2014
Last update
Sep 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00339183
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jun 20, 2006
Start date
Jun 30, 2006
Primary completion
Apr 1, 2009
Completion
Nov 1, 2010
Results posted
May 6, 2014
Last update
Sep 23, 2022

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panitumumab

Start the discussion